Creo Medical Group (LON:CREO) Shares Down 12.4% – Should You Sell?

Shares of Creo Medical Group PLC (LON:CREO) dropped 12.4% during mid-day trading on Wednesday. The company traded as low as GBX 9.90 and last traded at GBX 10.40. 7,994,368 shares were traded during mid-day trading, an increase of 921% from the average session volume of 783,030 shares. The stock had previously closed at GBX 11.88.

Analyst Ratings Changes

Separately, Shore Capital Group reissued a “house stock” rating and set a GBX 40 price objective on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Price Performance

The business’s 50 day moving average is GBX 12.77 and its two-hundred day moving average is GBX 12.87. The firm has a market capitalization of £50.52 million, a PE ratio of 10.40 and a beta of 1.56. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19.

Creo Medical Group (LON:CREO) last released its quarterly earnings results on Wednesday, September 30th. The company reported GBX (2) EPS for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. As a group, research analysts anticipate that Creo Medical Group PLC will post -10.0800005 EPS for the current year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.